Staff Reports
The Trump administration’s FDA is setting a new standard for how government should work for its people. Dr. Marty Makary, fresh into his role, is showing what true leadership looks like at the FDA. Under President Trump’s watch, the agency is prioritizing patient freedom and choice, throwing out the red tape that has plagued rare disease treatments for years. It’s refreshing to see a government body that understands every second counts for these young boys battling Duchenne muscular dystrophy.
Here’s a dose of reality: Duchenne is a cruel disease, stealing mobility, and life, from children too soon. But at last, there’s a beacon of hope in the form of a gene therapy called Elevidys. Originally put on a shelf by the FDA, the therapy is back, thanks to a quick pivot by the agency. Thank God someone in this bureaucracy decided to listen to the needs of real families rather than sticking to old, outdated methods. This isn’t just about treatment; it’s about giving American families the hope they desperately need.
Predictably, the naysayers and government skeptics are questioning the effectiveness of this treatment for certain groups. Fair enough. But here’s the kicker: When has government indecision ever truly helped anyone? Let’s be honest: When Washington drags its feet, it’s the afflicted who suffer, not the bureaucrats. President Trump’s push for the “Right to Try Act” was a monumental move to ensure that those on the front lines of these personal battles have every option possible. And now, Trump’s FDA is cutting through the bureaucratic nonsense to ensure these treatments reach the people who need them most.
Trump’s FDA Makes the Right Call on Duchenne Therapy https://t.co/TufBIyBzOH
— (((Charlie Martin))) (@chasrmartin) July 29, 2025
Why should government committees decide the fate of innovation when it’s clear that this therapy offers real benefits to those in the early stages of this devastating disease? Patients with rare conditions already know the risks, and the choice to try should be theirs. This is what liberty looks like, folks—putting health decisions back in the hands of those most affected. It’s about time the FDA functioned as a partner to patients instead of a barrier.
President Trump’s administration, with Dr. Makary at the FDA helm, is quickly redefining how we approach healthcare, focusing on patient choice and rapid action. This is what leadership feels like—a government working for the people, not against them. When will the liberals learn to cut the tape and let Americans do what Americans do best: tackle challenges head-on, without waiting for permission? Isn’t it time we stopped letting bureaucratic indecision snuff out hope?
